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The urokinase-typ¢ and tissue-type lasminogen activators are the two enzymes found in mammals, which specifically 
convert the zymogen plasminogen to plasmin. Using cDNA probes, wehave assayed for the presence ofthe two types 
of plasminogen activator mRNAs in routine tissues. We demonstrate that tissue-type lasminogen activator mRNA can 
be detected in a wide variety of tissues. In contrast, the accumulation f urokinase-type plasminogen activator mRNA 
is observed in only a few of the tissues analyzed. Using an S~ nuclease assay, we demonstrate that he tPA mRNA detected 
contains the complete s quences ncoding the non-protease finger, growth-factor and kringle domains. 
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1. INTRODUCTION 
The activation of the zymogen plasminogen to 
plasmin by plasminogen activators is associated 
with processes such as ovulation [1,2], embryo im- 
plantation [3], mammary gland involution [4], 
spermatogenesis [5], fibrinolysis [6] and in some 
instances metastasis [7,8]. Since plasminogen is a 
ubiquitous serum protein that permeates 
vertebrate tissues, much interest has centered on 
the role of plasminogen activators in these diverse 
physiologic events. There are two types of mam- 
malian plasminogen activators: tPA and uPA. 
These two proteins, the products of different 
genes, are antigenically distinct and their mRNAs 
can be distinguished from each other using nucleic 
acid probes [8]. It has now become apparent that 
the type of plasminogen activator produced and 
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the cell type expressing the enzyme are both impor- 
tant determinants of function. 
In humans and rodents, plasminogen activators 
have been observed in almost all tissues though at 
variable levels [9-14]. Three methods have general- 
ly been used to assay for the presence of 
plasminogen activators: enzyme assays of tissue 
extracts in conjunction with tPA and uPA anti- 
bodies [8], immunohistochemical analysis of tissue 
sections [12,13] and polyacrylamide gel electro- 
phoresis of tissue extracts followed by zymography 
[14,15]. All three methods allow distinction to be 
made between tPA and uPA. 
Interestingly, some investigators have observed 
tPA size heterogeneity [16-20]. One interpretation 
of these observations i that the lower molecular 
mass tPA molecules are the result of partial pro- 
teolysis, perhaps by plasmin, during extraction. In 
support of this proposal, plasmin has been used to 
remove domains from tPA in attempts to study the 
properties of the altered tPA enzyme [21]. Another 
possibility is that the tPA size heterogeneity could 
be the result of carbohydrate heterogeneity be- 
tween individual tPA molecules. With Bowes 
melanoma cells, for instance, two tPA proteins are 
observed that differ in molecular mass by 
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2-3 kDa, due to carbohydrate differences [22]. 
The results of Kagitani and collaborators [23], 
however, suggest another cause for the lower 
molecular mass tPA molecules. This group 
isolated ahuman tPA eDNA from Detroit 562 cells 
that lacks the sequences which code for the finger 
domain. Their results are consistent with alternate 
splicing of the tPA mRNA for the generation of 
additional forms of the enzyme. In addition, 
Nagamine and co-workers [24] have demonstrated 
the presence of two mRNAs for uPA which would 
generate proteins that differ in size by nine amino 
acids. Clearly, tissue-specific splicing of 
plasminogen activator transcripts would be of 
great significance in expanding the biological 
diversity of the plasminogen activator molecule. 
We were interested in whether there were other 
examples of altered forms of plasminogen ac- 
tivator, generated as a result of tissue-specific 
splicing. Using the mouse tPA eDNA as a probe, 
we have addressed this question by Northern blot 
and $1 analysis of mouse tPA mRNA. We also 
have determined the relative steady-state levels of 
uPA mRNA in mouse tissues. 
2. MATERIALS AND METHODS 
2.1. Animals 
Adult CD-I mice were supplied by Charles River (Wilm- 
ington, MA). For tissue dissection, animals were killed by CO2 
asphyxiation. 
2.2. RNA preparation and analysis 
The preparation of tissue RNA [25], Northern gel analysis 
[26] and dot blot analysis [27] were performed as described. To 
determine the relative levels of plasminngen activator RNA in 
tissues, dot blot autoradiograms were scanned using an LKB 
Ultrascan XL laser densitometer. The values obtained for the 
plasminogen activator samples were normalized using those ob- 
tained for 18 S rRNA to account for any variability in the 
amount of RNA present on the filters. 
2.3. Probe synthesis and hybridization conditions 
3zP-labeled tPA [28], uPA [29] and 18 S ribosomal [30] DNA 
probes were prepared using a random priming procedure [31]. 
Probe specific activities were routinely 0.8-2 x 109 cpm//~g. 
Hybridization and washing conditions were as in [28]. The 
nitrocellulose f'flters were washed for 30 rain with 50 mM 
NaOH at room temperature after autoradiography to remove 
radiolabeled DNA and allow successive filter hybridizations 
with tPA, uPA and 18 S ribosomal probes. 
2.4. Single-stranded DNA probe preparation and Sl protection 
assay 
Bacteriophage DNA was uniformly labeled with [3'P]ortho- 
phosphate in vivo as described [32]. The hybridizations and 
nuclease reactions were carried out as in [33] at a hybridization 
temperature of 52°C and using 500 U Sx nuclease (Sigma) for 
each protection assay. 
3. RESULTS 
Previously, we isolated a tPA cDNA from F9 
cells after cells were induced to differentiate using 
retinoic acid and dibutyryl cAMP. Characteriza- 
tion of the mouse cDNA revealed homology with 
the human tPA coding sequences with a finger, 
growth factor and two kringle domains [28]. As a 
preliminary step before analyzing tPA mRNA for 
tissue-specific splicing events, we used the mouse 
cDNA to assay murine tissues for the presence of 
tPA mRNA. 
To assay for tPA mRNA, 5-40/~g total cellular 
RNA from tissues was electrophoretically frac- 
tionated on denaturing formaldehyde/agarose 
gels, transferred tonitrocellulose and hybridized to 
a 32P-labeled tPA eDNA probe. The results from 
one experiment are shown in fig. 1. When the tPA 
cDNA was used as a probe, a transcript approx. 
2800 nucleotides in size was detected in most of the 
tissues. In contrast, detectable accumulation of 
uPA mRNA was observed only in the kidney and 
ovary. 
Overall, RNA was extracted from tissues on two 
or three separate occasions and analyzed for 
plasminogen activator RNA content by Northern 
gel and dot blot analysis. While tPA mRNA was 
detected in 20 out of 22 tissues analyzed, uPA 
mRNA accumulation was more restricted and 
observed, by this technique, only in the kidney, vas 
deferens and ovary. A summary of these results is 
shown in table 1. 
It should be noted that the Northern blot 
analysis performed with the tissue RNAs is not 
adequate for detecting small differences in com- 
position between the various tPA transcripts. For 
example, if a particular transcript lacked the 
growth factor or finger domain ( I l l  and 138 
nucleotides in length, respectively) these dif- 
ferences in molecular mass might not be detected. 
In addition, as discussed, there is one example 
where plasminogen activator mRNAs (uPA) dif- 
fered by 27 nucleotides [24]. Therefore, we used an 
S~ protection assay to screen the mouse tissue 
RNAs for the presence of differentially spliced 
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Fig. 1. Northern blot analysis of plasminogen activator mRNA in murine tissues. Total cellular RNA from various tissues was electro- 
phoretically fractionated on a denaturing 1 ¢/0 agarose gel, blotted and hybridized sequ ntially with 32p-labeled tPA and uPA probes. 
The amount of RNA analyzed was as follows: F9-RA/dbcAMP cells (F9 cells treated with retinoic acid and dibutyryl cAMP), 2.5/~g; 
thymus, 10/zg; uterus, adrenals, pituitary and brain stem, 15/zg; cerebrum, cerebellum, spleen, heart, small intestine, liver, lung, 
kidney, testis and ovary, 40/zg. Approximate sizes for the transcripts observed: tPA, 2.8 kb; uPA, 2.4 kb. 
tPA transcripts. We used as a probe M13.919. This 
M13 bacteriophage recombinant contains the 
nucleotide sequences encoding 16 amino acids of 
leader sequence, the finger domain, growth factor 
homology region, kringle no. 1 and. the sequences 
encoding 25 amino acids of kringle no. 2. M13.919 
bacteriophage DNA was uniformly labeled in vivo 
using [32p]orthophosphate to a specific activity of 
4.37 x 106//~g. The single-stranded bacteriophage 
DNA was hybridized to tissue RNAs for 14 h to 
allow duplex formation. Samples were then 
digested with $1 nuclease to degrade unprotected 
(non-duplexed) radiolabeled DNA. The nucleic 
acids, post-S1 treatment, were analyzed on 6°70 
acrylamide/8 M Urea gels. tPA transcripts present 
in murine tissues that have identity with F9 cell 
tPA generate a 675 bp fragment after $1 digestion 
(see F9-RA/dbcAMP, fig.2), RNA from F9 stem 
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Table 1 
Relative levels of plasminogen activator RNA in murine 
tissues a,b 
Tissue tPA c 
Uterus 100 
Oviduct 100 
Pituitary 69 
Cerebellum 49 
Heart 38 
Ovary 35 
Cerebrum 34 
Brain stem 31 
Kidney 30 
Lung 28 
Adrenal 15 
Testis 14 
Epididymis 14 
Trachea d 9 
Vas deferens 7 
Muscle 3 
Intestine 3 
Thymus 2 
Stomach 2 
Spleen 0.5 
Pancreas N.D. 
Liver N.D. 
a Relative levels of plasminogen activator RNA were deter- 
mined by dot blot analysis (see Section 2) 
b uPA RNA was observed only in kidney, vas deferens and 
ovary. While kidney and vas deferens contain similar 
amounts of uPA RNA, ovary contains 2% of the amount 
found in these tissues 
¢ Results reflect analysis of 2-3 separate RNA preparations. 
Amount of tPA RNA observed for uterine tissue given an ar- 
bitrary value of 100. N.D., none detected 
d Tracheal tissue samples contain, in addition, RNA from the 
thyroid and parathyroid 
• Dissected from hind limb 
cells and liver, which do not contain detectable 
amounts of tPA mRNA (as determined by Nor- 
thern blot analysis) served as negative controls. 
For all tissues containing tPA mRNA, only the 
675 bp fragment was observed (fig.2). 
4. DISCUSSION 
We have performed Northern gel and dot blot 
analysis with total cellular RNA to define mouse 
tissues that accumulate detectable amounts of tPA 
mRNA.  After obtaining this information, we used 
a portion of the mouse tPA cDNA to perform $1 
protection assays to determine whether tPA 
mRNAs were alternately spliced. Our results 
demonstrate hat the tPA mRNAs in these tissues 
encode a protein with the same non-protease struc- 
tural domains found for the F9 cell protein, tPA 
proteins translated from these RNAs should con- 
tain signal sequences, a growth factor homology 
region, finger domain and two kringles. The data 
suggest that the apparent molecular mass dif- 
ferences observed with tPA may be the result of  
proteolysis or carbohydrate differences. 
The results of this study should not be inter- 
preted as conclusive evidence that tissue specific 
tPA RNA splicing products do not exist. First, our 
study analyzed RNA from untreated animals. In a 
number of cell types, plasminogen activator pro- 
duction is subject to specific regulatory controls 
[34]. With rat granulosa cells, for instance, tPA 
mRNA accumulates only after exposure to 
gonadotropins [35]. It may be that additional 
forms of tPA RNA exist in mouse tissues, but they 
are not present at the time of killing. Alternatively, 
these RNAs may have been a minor component of 
the total tPA RNA population and therefore were 
not detected and/or  the cells producing these 
RNAs may constitute only a small percentage of 
the total tissue mass. With this in mind, it would 
be useful to determine for Detroit 552 cells [23] the 
percentage of 'finger-less' tPA RNAs present in 
the total tPA mRNA population. Similar studies 
for the two uPA mRNA transcripts [24] could also 
be performed. 
The two mammalian plasminogen activators, 
tPA and uPA, have the same substrate specificity, 
converting the zymogen plasminogen to plasmin. 
However, the plasminogen activator gene products 
are not similarly expressed in the mouse. While 
tPA mRNA is observed in the majority of the 
tissues analyzed, uPA mRNA accumulation is seen 
with only three of the tissues examined. The 
significance of this observtion is not clear, but the 
data are consistent with the production of the pro- 
tease tPA by a wide variety of tissues. 
Since the analysis of plasminogen activator 
RNA content was carried out in animals not 
treated with exogenous substances prior to killing, 
the factor(s) that could influence tPA gene expres- 
sion is (are) not known. However, it may be that 
the high levels of tPA mRNA in many tissues 
reflect, in part, that RNA production is con- 
stitutive. The accumulation of tPA mRNA does 
not necessarily ensure that proportionate l vels of 
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Fig.2. $1 protection analysis of tissue tPA mRNAs using MI3.9L9. M13.9L9 single-stranded bacteriophage DNA (120 ng, 
524000 cmp) was hybridized with the following amou t of total cellular RNA: (A) liver, 100/~g; F9-RA dbcAMP (F9 cells treated 
with retinoic acid and dibutyryl cAMP), 30/ag; testis, 50/zg; kidney, 50 #g; ovary, 50/~g; cerebrum, 50/zg; lung, 35/~g. (B) Fg-stem, 
100/zg; F9-RAC, 7.5/~g; uterus, 7.5/~g; oviduct, 7.5 #g; brain stem, 25/~g; heart, 25/~g; trachea, 15 #g; adrenal, 7.5/zg; epididymis, 
25/zg; cerebellum, 25/zg; vas deferens, 7.5/~g; spleen, 100/~g; stomach, 100/zg. Radiolabeled pBR322 HinfI restriction fragments were 
included as molecular m ss markers (lane M). 
extraceUular active enzyme will be produced; cer- 
tain ceils may exhibit translational control [36], or 
the cells producing tPA  may be able to regulate the 
extent to which the protein is secreted. Finally, 
plasminogen activator inhibitors may be present o 
regulate the levels of  enzyme activity. 
The present data document the accumulation of  
tPA  mRNA in a wide variety o f  murine tissues. 
However,  the question of  which cell types produce 
the observed tPA  mRNA is not addressed. One 
candidate is vascular endothelial cells which are 
known producers of  tPA  enzyme [37] and which 
would be present in all o f  our tissue preparations. 
However,  the fact that there were low or undetect- 
able levels of  tPA  mRNA in liver, intestine, and 
spleen - organs with considerable vascularization - 
suggests that in addition, other cell types produce 
the tPA  mRNA observed in our experiments. For 
example, tPA  can be synthesized by neurons 
[38,39], neuronal accessory cells [20], pituitary 
cells [ 13,40], pancreatic fl-cells [ 16], granulosa cells 
[2] and oocytes [36]. It is probable that many addi- 
t ional cell types produce tPA,  but these cell types 
have not been defined. 
Our  tissue survey, while not allowing us to iden- 
tify the cell types that produce tPA,  serves as good 
background information for defining tissue 
localization. The mouse tPA  cDNA should prove 
to be a useful probe for identifying in situ the cell 
types that produce tPA, which should lead to a 
better understanding of  tPA  gene expression. 
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